Commercial addition

Commercial addition

03.02.2016 - Swedish CDMO Recipharm has appointed Anke Mollowitz as Key Account Director Europe. Mollowitz joins from German contract manufacturer Aenova Group, where she was Head of Customer Service.

Mollowitz, who originally trained as translator and interpreter, worked in the machine manufacturing sector before joining Haupt Pharma Wülfing, an Aenova company, in 2005. After working as sales representative and project manager, she took the position as Head of Customer Service in 2013. Among other tasks she was responsible for acquisitions and business development within the Haupt Group.

At Recipharm, Mollowitz will be responsible for coordinating customer management and commercial aspects within the business management team.


01.02.2016 The position of head of the Bone Patient Value Unit at Belgian biopharma UCB, newly created just last year, has been filled. Pascale Richetta has taken on the job, and she will also serve as Executive Vice President and member of the Executive Committee at UCB.


Richetta has worked in the pharma sector for more than 20 years, most recently as Vice President Western Europe and Canada at AbbVie. Prior to that, she held several management positions at Abbott, GlaxoSmithKline, Ipsen and Servier. She studied medicine at the University of Poitiers, France.

At UCB, Richetta will be responsible for driving ahead the development of the company’s osteoporosis drug romosozumab.


27.01.2016 British drug developer e-Therapeutics plc has appointed Iain Ross as non-executive chairman. Ross holds similar appointments at Novogen, Biomer Technology, Anatara Life Sciences and several other companies.

© e-Therapeutics

Ross has worked in life science companies for more than 30 years. He was CEO of Celltech Biologics and CEO of Quadrant Healthcare. He also led Allergy Therapeutics towards its IPO and was Executive Chairman at Silence Therapeutics. Ross is Vice Chairman of the Council of Royal Holloway, London University.


25.01.2016 In mid-April, David Budd will join British biotech EpiStem as its new CEO and Director. Budd joins from Dx expert Leica Biosystems Amsterdam, where he worked as General Manager.

© EpiStem

Budd earned his Master's Degree in Molecular Biology from Canadian Queens University in 1992. He later served as Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc., before joining Leica Biosystems as Commercial Director.


20.01.2016 After stepping down from his position of CEO at Medigene, Frank Mathias is taking over as CEO of Rentschler Biotechnologie, a contract manufacturer based in Laupheim, Germany. Former CEO Nikolaus F. Rentschler, owner of the company, is moving on to the Supervisory Board.

© vfa

After studying pharmacy, Mathias started out at Hoechst AG, from where he went on to become CEO of the German subsidiaries of Servier and Amgen. He then became CEO of Medigene in 2009. Mathias is chairman of the vfa-bio and has already spent year on Rentschler’s Supervisory Board.

18.01.2016 Klaus Peter Kaspar joined the board of Immunodiagnostic Systems Holdings plc in December. The biochemist has more than 35 years of experience in the field of diagnostics.


From 2005 to 2011, Kaspar worked at bioMérieux, where he held the positions of Head of the microbiology unit and Head of the Global Research and Development. Before that he worked for Roche Diagnostics, formerly Boehringer Mannheim GmbH in various positions in Strategy, Business Development and R&D Management. He also serves as director at Daktari Diagnostics and Magellan bioConsult.


14.01.2016 James Sandy is taking over the clinical development of Immunocore’s immuno-oncology product pipeline as the company’s new Chief Development Officer. Sandy has 25 years of experience in the biotech and pharma sector.

© Immunocore

Most recently, he was Chief Development Officer at UK-based specialty pharmaceutical company Creabilis. Previously, Sandy held senior positions at Pfizer, among them Head of European and Asian Development Operations, Development Team Leader within the Gastrointestinal Therapeutic Area and Oncology Therapeutic Area Head, Europe. 

At the same time, Immunocore, a developer of T cell receptor-based biologicals for the treatment of cancer and other diseases, also appointed Julian Hirst as Director of Corporate Finance. 


11.01.2016 In December, Koos van Haasteren was appointed CEO of the Dutch sister companies Alloksys Life Sciences and Amrif. The new lead will be responsible for driving the development of the biopharma’s human recombinant RESCAP platform for both acute clinical settings and chronic diseases.

© Alloksys

Van Haasteren has previously worked at Saudi Arabian chemicals company SABIC, as well as at DSM and KPMG.


07.01.2016 London-based biotech Tiziana Life Sciences has hired James Tripp as its new Chief Operating Officer and Head of Global Clinical Operations. In his new role, Tripp will be responsible for all operations, including global clinical development for Tiziana.

© Tiziana

Tripp has over twenty years' experience in biopharmaceutical operations. Before joining Tiziana, he was Director, Clinical Management at Danish Novo Nordisk, A/S. Previously, he had worked at Regeneron Pharmaceuticals, Schering-Plough, Bayer and Roche.


04.01.2016 Martinsried-based Medigene AG has appointed current CSO Doloris Schendes to take over as new CEO of the Frankfurt-listed company. Medigene’s erstwhile CEO Frank Mathias is to be nominated for the Supervisory Board. The changes are taking effect 1 February, 2016.

© Medigene

Schendel holds a PhD in Genetics from the University of Wisconsin and is the author of more than 200 scientific publications. She has been a member of the scientific review board in several research organisations, among them the German Research Foundation, German Cancer Aid and the European Research Council.

Schendel joined Medigene in 2014 when the company acquired Trianta Immunotherapy. At Trianta, Schendel held the position of Managing Director. Prior to this, she was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich, and before that, she served as a University Professor for Immunology at Ludwig Maximilian University.


28.12.2015 Since December, clinical immunologist Robert K. Zeldin is leading the global clinical development, regulatory and medical affairs activities of Belgian biopharma company Ablynx.

© Ablynx

The newly appointed Chief Medical Officer earned his M.D. from the Tufts University School of Medicine in Boston and has held senior level clinical development positions at pharmaceutical companies, among them Merck and Novartis.

In his previous roles, Zeldin headed teams in immunology, respiratory, dermatology and cardiovascular disease where he was responsible for clinical development through to commercialisation and life cycle management. 

Zeldin replaces Dominique Tersago as CMO.

1/32Nächste Seite


Current issue

All issues

Product of the week


Job Advert


As a company at the leading edge of genomics, the focus at Illumina is research and development. We take our employees seriously. From colleagues to career path to meeting professional goals, we help you find opportunities to grow your career. more...


All videos

Stock list

All quotes


  • MAGFORCE (D)5.25 EUR5.00%
  • SUMMIT (UK)4.03 GBP3.87%


  • IMMUPHARMA (UK)25.50 GBP-12.07%


  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR22.9%
  • IXICO (UK)34.00 GBP15.3%


  • BIONOR PHARMA (N)0.88 NOK-43.6%
  • PROTHENA PLC (IE)34.27 USD-36.4%
  • PLETHORA (UK)2.75 GBP-33.3%


  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%


  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 07.02.2016


All Events